Elisabet De Los Pinos

Eli is the founder & CEO at Aura Biosciences, a clinical stage company developing a novel class of cancer drugs based on research at the National Cancer Institute. Prior to founding Aura, she worked at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for the treatment of Lung cancer. Eli obtained much of her oncology experience during a fellowship at Mount Sinai School of Medicine Institute of Molecular Medicine (NY, USA) and at Georgetown School of Medicine (Washington, DC). Later she worked as a post-doctoral fellow at the Institute of Cancer Research (London, UK). Eli holds a Magna Cum Laude Ph.D. in Molecular Biology from the University of Barcelona, an MBA from IE Business School and is a fellow of the Entrepreneurship Development Program at MIT Sloan School of Management (Cambridge, MA). She is a member of the Board of Overseers at the Museum of Science in Boston.
Awards:
Top 40 under 40 by the Boston Business Journal
Mass High Tech Woman to Watch
Technology Pioneer by the World Economic Forum
100 most intriguing entrepreneurs by Goldman Sachs